Trial Profile
Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine [RIX 4414] and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-Dose Primary Vaccination.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 13 Jan 2011 Results published in Vaccine.
- 12 May 2008 Status change
- 22 Oct 2006 New trial record.